IT DEPENDS ON YOUR PLAN
Does TRICARE Cover Wegovy?
Coverage Changed in August 2025
TRICARE coverage for Wegovy now depends on which plan you have.
- TRICARE Prime, Select, and related plans: Still cover Wegovy with prior authorization (PA)—your doctor must get approval before you fill the prescription
- TRICARE For Life (TFL): Lost coverage on August 31, 2025[1]
TRICARE coverage for Wegovy splits into three categories as of November 2025:
| TRICARE Plan | Wegovy for Weight Loss | Status | Notes |
|---|---|---|---|
| Prime | Covered with PA | Active | Step therapy + PA required |
| Prime Remote | Covered with PA | Active | Step therapy + PA required |
| Select | Covered with PA | Active | Step therapy + PA required |
| Young Adult | Covered with PA | Active | Step therapy + PA required |
| Reserve Select | Covered with PA | Active | Step therapy + PA required |
| Retired Reserve | Covered with PA | Active | Step therapy + PA required |
| US Family Health Plan | Covered with PA | Active | Step therapy + PA required |
| CHCBP (Continued Health Care Benefit Program) | Covered with PA | Active | Step therapy + PA required |
| TRICARE For Life (TFL) | NOT Covered | Ended 8/31/25 | Policy exclusion; diabetes drugs still covered |
| Direct Care Only | NOT Covered | Ended 8/31/25 | Military pharmacy access without plan enrollment |
Key takeaway: If you have TRICARE Prime, Select, or related plans, Wegovy IS covered—but you'll need to navigate PA and step therapy (trying lower-cost medications first). If you have TFL, weight loss drug coverage ended August 31, 2025.
WHAT HAPPENED TO TRICARE FOR LIFE?
The August 2025 Policy Change
TFL Coverage Ended August 31, 2025
On August 31, 2025, the Defense Health Agency (DHA) implemented "regulatory controls" that ended weight loss medication coverage for TRICARE For Life beneficiaries and those with direct care only.[1][2]
What Changed
DHA's official statement: "TRICARE has been providing coverage for weight loss medications to beneficiaries who were not eligible under federal statute. This implementation corrects that unauthorized coverage."[2]
This means:
- Even if you had an approved PA before August 31, it became invalid on that date
- You now pay 100% out of pocket for Wegovy, Zepbound, Saxenda, Qsymia, Phentermine, and Contrave if prescribed for weight loss
- No grandfathering—the change applied immediately to all TFL beneficiaries
What's Still Covered for TFL
Diabetes Indication Still Covered
GLP-1 medications (drugs that help control blood sugar and appetite) prescribed for Type 2 diabetes remain covered for TFL. This includes Ozempic, Mounjaro, and Victoza—with prior authorization.[1]
If you have diabetes, ask your provider if these medications might work for you.
Advocacy Response
The Military Officers Association of America (MOAA) has challenged this change, arguing it:
- Creates "two classes of drug coverage" between TRICARE and TFL beneficiaries
- Sets a dangerous precedent for future benefit reductions
- Has no clear legal basis—MOAA found no law specifically excluding TFL from GLP-1 coverage[1]
The advocacy effort is ongoing, but no immediate reversal is expected. TFL beneficiaries should explore alternatives (see Options if TRICARE Won't Cover).
TFL vs. Standalone Medicare
TRICARE For Life is NOT the same as standalone Medicare. TFL is a TRICARE plan that works alongside Medicare for military retirees.
Both TFL and basic Medicare Part D coverage exclude weight-loss drugs—but they have different rules and appeals processes. If you also have Medicare Part D, you may be able to get Wegovy through the Medicare GLP-1 Bridge ($50 per monthly fill, July 1, 2026 – December 31, 2027), with conditions. See our Medicare coverage guide for details.
TRICARE PRIME & SELECT
How to Get Wegovy Approved
For eligible TRICARE plans (Prime, Select, and related plans), Wegovy IS covered. However, you must meet several requirements to get approved.
Prior Authorization Requirements
Your provider must submit the Express Scripts PA form certifying:
| Requirement | TRICARE Criteria | Notes |
|---|---|---|
| Age | 12+ years old | Matches FDA indication |
| BMI Threshold | BMI (body mass index, a measure of weight relative to height) ≥30, or ≥27 with comorbidity (weight-related health condition) | Matches FDA indication |
| Qualifying Comorbidities | Hypertension (high blood pressure), dyslipidemia (high cholesterol), sleep apnea, metabolic dysfunction | Must have ICD-10 codes (medical diagnosis codes) documented |
| Lifestyle Documentation | 6 months diet/exercise that failed | Must be documented, not just attested |
| Step Therapy | Must fail 1 preferred drug | Phentermine, Qsymia, Saxenda, or Contrave |
| Ongoing Lifestyle | Must continue behavioral modification | Reduced-calorie diet throughout therapy |
| No Contraindications | No history of MTC (medullary thyroid cancer), MEN2 (a rare genetic condition affecting glands), pancreatitis (inflamed pancreas), or eating disorders | Uncontrolled high blood pressure also excluded |
| Initial Approval | 12 months | Renewal requires ≥5% weight loss |
PA Documentation Checklist
Required for TRICARE Wegovy Approval
- Current height and weight (within last 30 days)
- BMI calculation documented by provider
- 6-month lifestyle modification—actual documentation of diet/exercise program with insufficient weight loss
- Proof of step therapy—documented trial and failure (or contraindications) of at least one preferred drug
- Comorbidity diagnoses with ICD-10 codes:
- Obesity Class I (E66.811), Class II (E66.812), Class III (E66.813)
- Hypertension (I10)
- Dyslipidemia (E78.5)
- Obstructive Sleep Apnea (G47.33)
- No contraindications—confirmation of no thyroid cancer, MEN2, or pancreatitis history
- Provider-completed Express Scripts PA form
Your GLP-1 coverage,
denied approved
If TRICARE denies your Wegovy, Honest Care can help you build a strong appeal with evidence-backed documentation.
Denied by TRICARE?
Get Help NowWHAT TRICARE REQUIRES FIRST
Step Therapy Requirements
TRICARE enforces step therapy—a requirement that you try less expensive, preferred medications first before the insurance will approve more expensive drugs like Wegovy.[3]
| Drug | Form | Why TRICARE Requires It First | Common Issues |
|---|---|---|---|
| Phentermine | Oral tablet | More affordable, established, well-studied | Insomnia, elevated BP, anxiety |
| Qsymia | Oral capsule | Combination therapy, modest efficacy | Cognitive effects, increased HR |
| Saxenda | Daily injection | GLP-1 agonist, less potent than Wegovy | Daily injections, GI side effects |
| Contrave | Oral tablet | Unique mechanism, lower cost | Nausea, elevated BP |
Step Therapy Exception
If you've tried and failed a preferred drug in the last 180 days, or have documented contraindications to all preferred drugs, you may qualify for Wegovy without repeating step therapy.[3]
How to Document Step Therapy Failure
For your step therapy to count, your medical record must show:
- Drug name and dates of the trial period
- Duration (typically 3+ months adequate trial)
- Outcome—insufficient weight loss (<5%) or intolerable side effects
- Reason for discontinuation documented by provider
For more on navigating prior authorization and step therapy requirements, see our prior authorization guide.
CLARIFYING THE OSA INDICATION
Sleep Apnea & Wegovy
Important: Wegovy is NOT FDA-Approved for OSA
Wegovy (semaglutide) is not FDA-approved for obstructive sleep apnea. On December 20, 2024, the FDA approved Zepbound (tirzepatide)—not Wegovy—as the first medication specifically for moderate-to-severe OSA in adults with obesity.[4]
What This Means for TRICARE Coverage
Since Wegovy is not FDA-approved for OSA, TRICARE will not cover Wegovy specifically for sleep apnea treatment. The OSA pathway that bypasses step therapy applies only to Zepbound, not Wegovy.
However, if you have both obesity and sleep apnea, there are still options:
- Pursue Wegovy for weight management—Sleep apnea is a qualifying comorbidity that can support your PA for Wegovy under the obesity indication
- Consider Zepbound instead—If OSA is your primary concern, Zepbound has the FDA-approved OSA indication and may have different coverage requirements. See our TRICARE Zepbound guide
- Document sleep apnea as a comorbidity—Having diagnosed OSA (ICD-10: G47.33) strengthens your medical necessity case for weight management coverage
Why Sleep Apnea Helps Your Wegovy Case
Wegovy is not approved for OSA, but having sleep apnea documented in your medical records can help your TRICARE weight-management approval because:
- OSA qualifies as a weight-related comorbidity for the BMI ≥27 threshold
- Weight loss may improve sleep apnea symptoms
- It demonstrates medical necessity beyond "cosmetic" weight loss
If You Have Sleep Apnea
Make sure your sleep study results (documenting AHI score) and OSA diagnosis are in your medical records. This documentation strengthens your prior authorization request for Wegovy under the weight management indication, even though Wegovy is not approved for OSA.
TRICARE WEGOVY COPAYS
What You'll Pay
Wegovy is a non-formulary brand-name drug on TRICARE's formulary (list of covered medications). Non-formulary means it's not a preferred drug, so you'll pay higher copays. Costs vary by where you fill your prescription.[5]
| Point of Service | 2025 Copay | 2026 Copay | Notes |
|---|---|---|---|
| Military Pharmacy (MTF) | $0 | $0 | Generally not stocked for non-formulary |
| TRICARE Home Delivery (90-day) | $76 | $85 | Best value for maintenance fills |
| Retail Network (30-day) | $76 | $85 | Same as home delivery for non-formulary |
| Non-Network Pharmacy | 20-50% cost-share | 20-50% cost-share | After deductible; full pay upfront, then reimbursement |
Active Duty Service Members
$0 copay at all points of service—military pharmacies, retail network, and home delivery. Active duty copays remain unchanged in 2026.[5]
Without Coverage
If you're a TFL beneficiary or otherwise don't have coverage:
- List price: $1,349/month
- NovoCare self-pay: $349/month ($399 for Wegovy HD 7.2 mg) (If you have government insurance, ask NovoCare whether you can use self-pay pricing; see alternatives below)
- Medicare Part D enrollees (including TFL): the Medicare GLP-1 Bridge covers Wegovy for $50 per monthly fill, with conditions
EXPRESS SCRIPTS PROCESS
How to Submit Your PA
Search TRICARE Formulary
Go to the TRICARE Formulary Search Tool and search "Wegovy" to confirm coverage status and download the PA form.
Download the PA Form
Download the "TRICARE Prior Authorization Request Form for Wegovy" (semaglutide injection form).
Provider Completes Form
Your prescriber must fill out clinical assessment questions including BMI, prior treatments, comorbidities, and step therapy documentation.
Submit to Express Scripts
- Phone: 1-866-684-4488
- Fax: 1-866-684-4477
- Email: TPharmPA@express-scripts.com
- Mail: Express Scripts, P.O. Box 52150, Phoenix, AZ 85072-9954
Wait for Determination
Typically ~10 days after Express Scripts receives the complete form. Initial approvals are for 12 months.[6]
Active Duty Note
Even if coverage will not be approved, the PA form must initially be submitted to Express Scripts. Subsequent reconsideration is allowed at your Military Treatment Facility.[3]
COMMON TRICARE DENIAL REASONS
Why Your Claim Was Denied
| Denial Reason | What It Means | How to Fix |
|---|---|---|
| Plan exclusion (TFL/direct care) | You're on TRICARE For Life or direct care only—weight loss drugs ended Aug 31, 2025 | Appeal unlikely to succeed; consider Zepbound for OSA or cash pay options |
| Step therapy not met | No documented trial and failure of Phentermine, Qsymia, Saxenda, or Contrave | Document trial and failure of at least one preferred drug |
| BMI too low | BMI <27, or BMI 27-29 without documented comorbidity | Document comorbid conditions (hypertension, dyslipidemia, sleep apnea) |
| Insufficient lifestyle documentation | No proof of 6-month diet/exercise trial | Provide weight logs, dietitian notes, exercise records |
| Missing diagnosis code | Prescription didn't include medically accepted indication | Ensure provider submits with the correct ICD-10 for obesity (plus any comorbidities) |
| Contraindication flagged | History of MTC, pancreatitis, eating disorder in records | Provide updated records showing contraindication resolved or misapplied |
Understanding why you were denied is key to winning your appeal. Ask for the denial in writing with the exact reason code.
TRICARE PHARMACY APPEALS
How to Appeal
Filing Your Appeal
You have 90 days from the denial notice postmark to submit a pharmacy appeal to Express Scripts.[7]
What to Include in Your Appeal
- Written, signed appeal letter explaining why you disagree
- Copy of the denial decision from Express Scripts
- Supporting documentation addressing the specific denial reason
- Letter of Medical Necessity from your prescriber
- Updated medical records (weight, BMI, comorbidities)
- Clinical evidence—research showing Wegovy produces 15-21% weight loss
Where to Send Your Appeal
Express Scripts Appeal Address
Mail: Express Scripts, Inc., P.O. Box 60903, Phoenix, AZ 85082-0903
Fax: Use the number on your denial letter
Phone (questions): 1-877-363-1303
Appeal Timeframes
- Standard appeal: Decision within 30 days
- Expedited appeal: 72 hours (if urgent medical need documented by provider)
- Second level appeal: If first appeal denied, you can request further review
Realistic Expectations
| Denial Type | Appeal Likelihood | Why |
|---|---|---|
| Procedural (missing docs, step therapy) | Good success rate | If you provide the missing evidence, criteria can be met |
| Plan exclusion (TFL policy) | Very low success rate | DHA says this is a policy decision, not reviewed case-by-case |
For detailed appeal strategies, see our complete Wegovy appeals guide.
YOUR OPTIONS
If TRICARE Won't Cover
If you're facing a denial or exclusion, here are your options:
1. NovoCare Self-Pay (Not Patient Assistance)
- Wegovy is not on Novo Nordisk’s Patient Assistance Program list, so free Wegovy through patient assistance isn't an option
- NovoCare self-pay: $349/month ($399 for Wegovy HD 7.2 mg); If you have government insurance, ask NovoCare whether you can use self-pay pricing
- See our Wegovy cost guide for NovoCare details
2. Wegovy Savings Card
- Novo Nordisk savings card can reduce cost to as little as $25 for commercially insured patients
- Only works if Wegovy is covered by your insurance—does NOT work for TFL exclusions or government programs
- See our Wegovy cost guide for savings card details
3. Diabetes-Indication Coverage
- If you have Type 2 diabetes, ask your provider about Ozempic (same active ingredient as Wegovy—semaglutide)
- Ozempic IS covered on TRICARE with PA for diabetes—even for TFL
4. Sleep Apnea as Comorbidity
- If you have diagnosed OSA (AHI ≥15), use it as a comorbidity to strengthen your Wegovy PA for weight management
- Note: Wegovy is NOT FDA-approved for OSA—only Zepbound has this indication. See our Zepbound TRICARE guide
5. Alternative GLP-1s
- Check if Saxenda has different formulary status—it's a preferred drug on TRICARE
- Saxenda may have lower copay and easier approval than Wegovy
6. Professional Appeal Service
- Consider professional appeal writing services (like Honest Care) for complex denials
- Evidence-backed appeals with clinical citations
SPECIAL RULES
Active Duty Service Members
Zero Copay Benefit
Active duty service members pay $0 copay at military pharmacies, network retail pharmacies, and TRICARE Home Delivery—both in 2025 and 2026.[5]
Key Considerations for Active Duty
- Medical necessity required for non-formulary drugs including Wegovy
- Military Treatment Facility (MTF) formulary restrictions: Military pharmacies generally don't stock non-formulary drugs unless medically necessary
- Command requirements: May need to follow Military Department-specific policies for weight management programs
- PA process: Even if coverage will not be approved, PA form must be submitted to Express Scripts first; subsequent reconsideration allowed at your MTF
Fitness standards: If weight loss is related to meeting fitness standards, work with your unit's medical team to document medical necessity appropriately.
WHAT'S CHANGING
2026 Outlook
TRICARE's coverage split (Prime/Select covered, TFL excluded) will likely stay the same through 2026. Non-formulary copays rose from $76 to $85 on January 1, 2026.
If you have TRICARE For Life and Medicare Part D, the Medicare GLP-1 Bridge may cover Wegovy for weight loss; check our Medicare guide.
TRICARE WEGOVY COVERAGE
Frequently Asked Questions
It depends on your plan. TRICARE Prime, Select, Young Adult, Reserve Select, Retired Reserve, US Family Health Plan, and CHCBP cover Wegovy with prior authorization and step therapy. TRICARE For Life and direct care only beneficiaries lost coverage on August 31, 2025.
DHA says TFL was covering weight loss drugs for people "not eligible under federal law." The change matches Medicare's weight loss drug exclusion. MOAA has challenged this decision, but no reversal is expected soon.
No—Wegovy is not FDA-approved for sleep apnea. Only Zepbound has this approval (December 2024). However, sleep apnea counts as a comorbidity that can help your Wegovy weight loss approval. If sleep apnea is your main concern, ask about Zepbound instead.
You must try and fail (or have documented contraindications to) at least one of: Phentermine, Qsymia, Saxenda, or Contrave. If you've failed a preferred drug in the last 180 days, you may get automatic approval for Wegovy.
With approved coverage: $76 copay (2025) or $85 (2026) for 30-day retail or 90-day home delivery. Active duty service members pay $0 at all points of service. Without coverage (TFL, direct care): list price $1,349/month, or NovoCare self-pay at $349/month ($399 for Wegovy HD 7.2 mg) (if you have government insurance, ask NovoCare whether you can use self-pay pricing). Wegovy is not on Novo Nordisk's patient assistance list.
Yes. You have 90 days from the denial postmark to submit a pharmacy appeal to Express Scripts. Procedural denials (missing step therapy, insufficient documentation) can be addressed by providing the missing evidence. Plan exclusion denials (TFL policy) are very difficult to overturn.
TRICARE covers Ozempic (same active ingredient as Wegovy—semaglutide) for Type 2 diabetes with prior authorization. It's NOT covered for weight loss. If you have Type 2 diabetes, this may be an option even for TFL beneficiaries.
Approximately 10 days after Express Scripts receives the complete PA form. Initial approvals are for 12 months. Renewal requires documentation of ≥5% weight loss from baseline.
YOUR PATH FORWARD
What's Next
Wegovy Coverage: Other Insurance Options
Coverage varies significantly by program type. See our guides:
- Medicare — basic Part D coverage excludes weight loss; the Medicare GLP-1 Bridge (outside Part D) covers Wegovy (with conditions)
- Medicaid — 13 states cover for obesity
- Blue Cross Blue Shield — Major 2026 coverage restrictions
- UnitedHealthcare — Coverage varies by plan
- Aetna — Most plans cover with prior authorization
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedReferences
- MOAA. (2025). "Weight-Loss Drug Coverage Ends for TRICARE For Life Beneficiaries: What's Next?" moaa.org
- TRICARE Newsroom. (2025). "TRICARE Coverage of Weight Loss Medications: What To Know." tricare.mil
- TRICARE. (2025). "Step Therapy." tricare.mil
- FDA. (2024). "FDA Approves First Treatment for Obstructive Sleep Apnea." fda.gov
- Express Scripts. (2025). "Changes to your TRICARE prescription drug copayments in 2026." militaryrx.express-scripts.com
- TRICARE Newsroom. (2025). "Getting Prior Authorizations for TRICARE Prescriptions: Your Questions Answered." tricare.mil
- TRICARE. (2025). "Pharmacy Appeals." tricare.mil
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.